FDA Alert
FDA Alert
09/27/2024
Anthony Calabro, MA
The nasal spray is the first vaccine for the prevention of influenza that does not need to be administered by a health care provider.
09/27/2024
FDA Alert
FDA Alert
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
07/31/2024
Anthony Calabro, MA
The first orally disintegrating birth control tablet was designed for individuals who have trouble swallowing their medication.
07/31/2024
Research summary
Research summary
06/06/2024

Jessica Ganga

Jessica Ganga
Researchers conducted a meta-analysis to determine the global prevalence of unprescribed weight-loss product use, such as diet pills, among adolescents.
06/06/2024
COVID-19 Roundup
COVID-19 Roundup
05/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
In this COVID-19 roundup, the CDC reports a record low number of COVID-19 hospitalizations, metformin reduces the likelihood of SARS-CoV-2 Viral load and rebound, remdesivir reduces mortality in older...
05/21/2024
FDA Alert
FDA Alert
04/18/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.
04/18/2024
Research Summary
Research Summary
03/27/2024

Anthony Calabro, MA

Anthony Calabro, MA
Nearly 108,000 Americans died of overdoses in 2022, surpassing the previous year’s record total, according to a CDC report. Although the official number of deaths caused by overdoses—107,941—breaks the...
03/27/2024
FDA Alert
FDA Alert
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
03/21/2024